Home › Osteoporosis › NCT06558188

Combined Anabolic Therapy

Combined Anabolic Therapy Study

Who can join

Ages 45 and older · Women · Healthy volunteers welcome

Inclusion Criteria:

* women aged 45+
* postmenopausal
* osteoporotic with high risk of fracture

Exclusion Criteria:

* no significant previous use of bone health modifying treatments
* known congenital or acquired bone disease other than osteoporosis
* significant renal disease, liver disease, cardiopulmonary disease, or psychiatric disease
* abnormal calcium or parathyroid hormone level
* serum vitamin D \<20 ng/dL
* anemia (hematocrit \<32%)
* history of malignancy (except non-melanoma skin carcinoma)
* excessive alcohol use or substance abuse
* known contraindications to romosozumab or teriparatide

About the study

In this research study the study investigators want to learn more about the effect of two different FDA-approved medication regimens in the treatment of postmenopausal osteoporosis.

What is being tested

• Romosozumab (drug)
• Teriparatide (drug)

Sponsor: Massachusetts General Hospital · Participants: 50 · Started: Feb 3, 2025

Contact the study team

• Aparna Patnaik, BA · Phone: 617-726-6129

Official record on ClinicalTrials.gov — NCT06558188

Locations in the U.S.

Conditions

• Osteoporosis

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.